Topical compositions incorporating silica fibers

Silica fiber compositions prepared by sol-gel electrospinning solve the problem of poor skin aging and damaged skin integration in the prior art, providing soft fiber compositions to simulate collagen, improve skin healing and relieve pain and inflammation, achieving improved collagen deposition and skin integration.

CN111989089BActive Publication Date: 2024-11-08美国纳米有限责任公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980025783.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-09-10
Filing Date
2019-03-28
Publication Date
2024-11-08
Estimated Expiration
2039-03-28

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve the integration of skin aging and damaged skin, the collagen supplements are poorly absorbed, and the existing fibrous compositions lack flexibility and suitable texture, making it difficult to simulate collagen deposition and reduce pain and inflammatory mediators.

Method used

Using silica fiber compositions prepared by sol-gel electrospinning, soft fiber pads are formed and processed into fiber dust or fragments blended with local carriers for skin care and providing non-biodegradable cell scaffolds to promote collagen deposition and reduce pain and inflammatory mediators.

Benefits of technology

Improves skin healing, reduces scarring and signs of aging, reduces pain and inflammation, provides soft fiber compositions to mimic collagen, and improves skin integration and tolerance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111989089B_ABST
    Figure CN111989089B_ABST
Patent Text Reader

Abstract

Embodiments of the present invention include topical compositions for treating skin tissue comprising a silica fiber powder or dust and a topical carrier. The silica fiber powder or dust may be generated from a silica fiber mat formed via electrospinning of a sol-gel produced with a silane oxide reagent such as tetraethyl orthosilicate, an alcohol solvent, and an acid catalyst.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 729,085, filed on September 10, 2018, and U.S. Provisional Patent Application No. 62 / 651,386, filed on April 2, 2018, the entire disclosure of each of which is hereby incorporated by reference. Technical Field

[0003] In various embodiments, the present invention is directed to topical compositions incorporating silica fibers as an additive. Background Art

[0004] Collagen is a protein that provides the matrix that maintains the body's structure. It provides integrity, firmness and elasticity to tissues. Loss of collagen leads to wrinkles, lines and loss of smoothness associated with skin aging. Because collagen is not absorbed through the skin in significant amounts, nutritional supplements are sometimes used to boost collagen levels, although collagen is also poorly absorbed as a dietary supplement.

[0005] There is a great need for topical products that improve the integrity of skin, including aged or damaged skin. Summary of the invention

[0006] According to various embodiments, the present invention provides topical compositions comprising silica fiber powder or dust (e.g., a collection of fiber fragments) and a topical carrier. Embodiments of the present invention also provide methods for treating aging or damaged skin of a subject. In various embodiments, the method includes applying the composition to improve skin healing, to prevent or reduce scarring, to reduce signs of aging, and / or to relieve pain and / or irritation associated with damaged or diseased skin.

[0007] In various embodiments, the topical composition, when applied to the skin, allows the silica fiber dust to be deposited in macroscopic or microscopic cracks in the skin. The fiber dust or flakes can serve as a collagen mimic that is substantially non-biodegradable and can promote cell infiltration and / or collagen deposition, and in some embodiments, reduces local pain and the generation of inflammatory mediators. The topical carrier can be in the form of an emulsion, an ointment, a paste, a cream, a foam, a balm, a soap, a shampoo, or a gel, and can include other active agents.

[0008] According to various embodiments, the fiber composition is prepared by electrospinning the sol-gel into a silica fiber composition, then processing the fiber into a fine powder or dust, and blending the powder or dust with a local carrier. In some embodiments, the silica fiber composition is electrospun into a lightweight fiber mat from a gel-like material. For example, the composition can be prepared by electrospinning a sol-gel, which can be prepared with a silane oxide reagent (such as tetraethyl orthosilicate (TEOS)), an alcohol solvent, and an acid catalyst. In various embodiments, the sol-gel is produced by ripening the sol under controlled environmental conditions, and / or the properties of the sol or sol-gel are monitored during the ripening process to identify various processing windows in which the electrospinning of the sol-gel can be successfully performed. As known in the art, a "sol" is a colloidal solution that gradually evolves to form a "gel", that is, a two-phase system containing both a liquid phase and a solid phase. In this article, the term "sol-gel" is used to refer to a gel that can be electrospun into a fiber or a fiber mat produced from a sol-gel process.

[0009] The known process for electrospinning silica fibers cannot produce a fiber composition with sufficient flexibility and a texture suitable or desirable for many applications. By slowly ripening the sol-gel under controlled environmental conditions and / or monitoring the sol-gel during the ripening process, the relatively short window of successful electrospinning sol-gel can be determined and its duration can be increased. According to an embodiment of the present invention, the composition is non-rigid and has a soft texture similar to cotton. In some embodiments, after the ripening process of at least 2 days or at least 3 days (such as 2 to 7 days) under controlled environmental conditions, the sol-gel is electrospun. The weight of the sol-gel and / or the emission of ethylene vapor can be used as an indicator of when the sol-gel is in or close to the ideal time for electrospinning.

[0010] In various embodiments, the controlled environment for ripening (or "conversion") the sol may involve controlled conditions in terms of humidity, temperature, and optional atmospheric pressure. For example, the humidity may be controlled in the range of about 30% to about 90% or about 40% to about 80%, and the temperature may be controlled in the range of about 50°F to about 90°F. By controlling the environmental conditions during ripening, the gel may be electrospun during the optimal time for spinning, and if the ripening process is accelerated by direct heating, electrospinning may occur in a very small window of only a few minutes. When the sol is ripened at a constant humidity in the range of about 50% to 70% or 80% and at a temperature of about 60°F to 80°F, the sol will ripen (gel) within a few days, and the window for successful electrospinning may be extended to at least a few hours, and in some embodiments, a few days. Therefore, the sol may be ripened in an enclosure that may include one or more environmental monitors (such as a temperature reading device and / or a humidity reading device). Further, the gases generated or released from the sol and / or the relative weight of the sol during the aging process can be monitored to determine a suitable or optimal time for electrospinning.

[0011] Once the sol is fully matured into a sol-gel, it is electrospun to form a tangled silica fiber mat. Once electrospun, the silica fiber may have a variable diameter such as in the range of about 50nm to 5μm. In some embodiments, the fiber is mainly in the range of about 100nm to about 2μm, or mainly in the range of about 200nm to about 1000nm. After the silica fiber mat is successfully formed, it is separated into small fiber fragments in various embodiments, and the fiber fragments are used as additives in any of a variety of different topical compositions. For example, the electrospun mat can be "fragmented", that is, broken, cut, ground, milled or otherwise separated into small fragments that maintain a fiber structure. As used herein, the term "fiber fragment" (or "fiber mat fragment", or simply "fragment") refers to a small particle, part or flake of a fiber mat, the average size of which is larger than the width of at least some fibers of the mat (e.g., 5 times, 10 times or even 100 times). In various embodiments, the average size of the fiber fragments is in the range of about 20 μm to about 200 μm. Thus, the fiber fragments may resemble a microscopic scale form of the electrospun mat itself, such as a collection of silica fibers tangled together, and are therefore generally porous and have a low density. Thus, the fiber fragments may be contrasted with other types of micron-sized particles, which are substantially spherical particles such as those used in colloidal silica, each of which is a single, individual unit or particle, rather than a small collection of fibers. Portions (e.g., edges) of the fiber fragments may have sharp and / or broken edges resulting from the breaking process used to form the fragments from the electrospun mat. As used herein, the term "fiber dust" includes a collection of particles produced via fragmentation of an electrospun fiber mat and / or fibers, and may include fiber fragments and / or other powder particles produced by such fragmentation.

[0012] Embodiments of the present invention may utilize silica fibers, fragments thereof, and / or compositions incorporating such fibers or fragments, and / or methods for making such fibers or fragments (described in detail in U.S. patent application Ser. No. 15 / 934,599 filed on Mar. 23, 2018 (granted as US 10,111,783) and U.S. patent application Ser. No. 16 / 131,531 filed on Sept. 14, 2018), the entire disclosure of each of which is incorporated herein by reference.

[0013] Fiber dust or fiber fragments are blended with a topical carrier. The topical composition can be a skin care composition or a cosmetic composition. In some embodiments, the fiber dust or fragments are distributed in a carrier system such as water or any aqueous solution containing organic or inorganic materials. The composition can contain one or more ingredients to change or enhance its texture, appearance, odor performance or stability. Exemplary additives of the composition include: oily components, fatty components, ointment bases, hydrophilic solvents, lipophilic solvents, emollients, water, buffers, pH regulators, preservatives, wetting agents, chelating agents, antioxidants, stabilizers, emulsifiers, suspending agents, gel forming agents, perfumes and flavors, skin protectants and preservatives.

[0014] In some embodiments, the composition further comprises one or more anti-inflammatory agents, such as steroidal anti-inflammatory agents or non-steroidal anti-inflammatory agents (NSAIDs). In some embodiments, the composition further comprises one or more antimicrobial agents. In some embodiments, the composition further comprises one or more pain relievers.

[0015] In various embodiments, the invention provides a method for treating skin tissue in a subject, the method comprising applying a topical composition to the skin tissue. The composition can be used routinely or regularly. In some embodiments, the composition is applied at least about every day. In various embodiments, the method improves the healing of skin tissue and / or prevents or reduces tissue scarring, skin laxity, age spots, pain and / or irritation.

[0016] Application of the composition can provide improved or accelerated healing of damaged skin. For example, when the topical composition is applied to skin with cracks, small scrapes, blemishes, etc., the scaffold will remain in the small "wounds" to allow cells to grow in. This speeds up the healing process and helps reduce scarring. In some embodiments, the composition is applied to cracked skin, which can improve the skin's tolerance to the environment (such as sunlight, wind, and cold).

[0017] In some embodiments, the composition is applied to skin lesions, superficial wounds or infections, acne, burns, ulcers, cuts, abrasions, rashes, blisters, allergic reactions, urticaria, or insect or spider bites or stings. Exemplary conditions include aging skin, dry skin, eczema, itching, sunburns, reactions to poison ivy or poison oak, postoperative wounds, skin grafts, insect bites, and genetic diseases that affect skin integrity (such as, but not limited to, epidermolysis bullosa and ichthyosis). In some embodiments, the composition is applied to diseased skin, which may be a manifestation of a proliferative disorder (cancer or precancer, such as melanoma lesions or psoriasis), or in some embodiments, a manifestation of an autoimmune or inflammatory disorder (such as rosacea, acne, skin manifestations of lupus, or dermatitis herpetiformis). In some embodiments, the composition is applied to a microbial infection of the skin. In some embodiments, the composition is applied to skin affected by herpes zoster, thereby providing, for example, relief of associated pain. Other conditions that may benefit from the pain-relieving properties of the present invention include neuropathy, arthralgia, and gout.

[0018] In one aspect, embodiments of the invention feature a topical composition comprising, consisting essentially of, or consisting of: a silica fiber powder or dust, and a topical carrier.

[0019] Embodiments of the present invention may include one or more of the following, in the form of any combination of various combinations. The topical carrier may be an emulsion, an ointment, a balm, a paste, a cream, a foam, a soap, a shampoo, a bath salt and / or a gel. The composition may also include one or more medicaments or antimicrobial agents. The composition may also include an antibiotic and / or an antiseptic. The composition may also include an anti-inflammatory agent, an immunosuppressant and / or a pain reliever. The composition may also include an anti-fibrotic agent and / or an anti-scarring agent.

[0020] The composition can be prepared by electrospinning a sol-gel into a silica fiber composition, processing the silica fiber composition into a powder or dust and blending the powder or dust with a topical carrier. The sol-gel can be prepared using tetraethyl orthosilicate (TEOS). Before the sol-gel is electrospun, the sol-gel can be produced from an initial sol comprising, consisting essentially of, or consisting of: 70% to 90% by weight of TEOS, 8% to 25% by weight of ethanol, an acid catalyst, and water. The initial sol can comprise, consist essentially of, or consist of: 70% to 90% by weight of TEOS, 8% to 25% by weight of ethanol, an acid catalyst, and water. The initial sol can contain 70% to 90% by weight of TEOS, 8% to 25% by weight of ethanol, an acid catalyst, and a balance of water. The initial sol may comprise, consist essentially of, or consist of 70 to 90 wt % of TEOS, 8 to 25 wt % of ethanol, an acid catalyst, and water. The initial sol may contain 70 to 90 wt % of TEOS, 8 to 25 wt % of ethanol, an acid catalyst, and a surplus of water. The initial sol may comprise, consist essentially of, or consist of 70 to 90 wt % of TEOS, 8 to 25 wt % of ethanol, an acid catalyst, and water. The initial sol may comprise, consist essentially of, or consist of 70 to 90 wt % of TEOS, 8 to 25 wt % of ethanol, an acid catalyst, and water. The initial sol may comprise, consist essentially of, or consist of 70 to 90 wt % of TEOS, 8 to 25 wt % of ethanol, 1 to 10 wt % of water, and an acid catalyst. The initial sol may comprise, consist essentially of, or consist of 75 to 85 wt % of TEOS, 12 to 20 wt % of ethanol, and about 2 to 5 wt % of water. The initial sol may comprise, consist essentially of, or consist of about 80 wt % TEOS, about 17 wt % ethanol, and about 3 wt % water. The acid catalyst may comprise, consist essentially of, or consist of HCl. The initial sol may contain less than about 0.1 wt % of the acid catalyst. The initial sol may contain 0.02 wt % to 0.08 wt % of the acid catalyst. The initial sol may contain one or more agents that change one or more properties of the initial sol, sol-gel, and / or silica fibers.

[0021] The preparation of sol-gel may include transforming the initial sol under conditions of humidity in the range of about 40% to about 80% and temperature in the range of 50°F to 90°F for at least 2 days. The initial sol may be transformed for at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days. The initial sol may be transformed for 2 to 10 days, and in some embodiments for 2 to 7 days. The sol-gel may be electrospun when the weight is 20% to 40% of the starting weight of the initial sol or sol-gel before maturation (transformation). The sol-gel may be electrospun when the yield of ethylene vapor is 10% to 20% of the peak yield of ethylene vapor during maturation (transformation) of the initial sol or sol-gel before maturation. The sol-gel may be electrospun when the yield of ethylene vapor from the sol-gel is 10% to 40% relative to the initial sol or sol-gel before maturation (transformation). The powder or dust may comprise, consist essentially of, or consist of particles and / or fiber fragments that may have an average size (e.g., average diameter, length, width, or other dimension) ranging from about 20 μm to about 200 μm. The fibers may have a variable diameter of about 50 nm to about 5 μm. The fibers may have a variable diameter of about 200 nm to about 1000 nm. The silica fiber powder or dust may consist essentially of or consist of SiO2.

[0022] In another aspect, embodiments of the invention feature methods for treating skin tissue in a subject. The method can include, consist essentially of, or consist of applying a topical composition to the skin tissue. The topical composition comprises, consists essentially of, or consists of a silica fiber powder or dust, and a topical carrier. The topical composition can comprise, consist essentially of, or consist of any topical composition described herein.

[0023] Embodiments of the present invention may include one or more of the following, in the form of any combination of various combinations. The method can improve the healing of skin tissue and / or prevent or reduce tissue scarring, pain and / or irritation. The subject can be a mammal. The subject can be a veterinary patient, such as a dog, cat or horse. The subject can be a human patient. The composition can be applied to skin lesions, scars, superficial wounds or infections, burns, cuts, abrasions, rashes, blisters, insect bites, poison ivy or poison oak and / or urticaria. The subject can suffer from a genetic disease of the skin, such as epidermolysis bullosa or ichthyosis. The subject can have a first, second or third degree burn, or a combination thereof. The composition can be applied to sunburns. The composition can be applied to melanoma lesions. The composition can be applied to aging skin, age spots, dry skin, cracked skin and / or scar tissue. The composition can be applied to skin affected by eczema and / or atopic dermatitis. The composition can be applied to skin affected by psoriasis. The composition can be applied to skin affected by acne and / or rosacea. The composition can be applied to postoperative wounds and / or sutures (e.g., sutures for at least partially closing wounds). The composition can be applied to skin affected by itching. The composition can be applied to skin affected by herpes zoster and / or lupus. The subject may be affected by neuropathy, arthralgia, and / or gout. The composition can be applied to skin affected by dermatitis herpetiformis and / or dermatomyositis. The composition can be applied to skin showing signs of microbial infection and / or skin infected by one or more microorganisms (such as viruses, bacteria, or fungi). Microbial infection can be HPV, herpes simplex virus, varicella zoster virus, fungal infection, and / or Staphylococcus aureus infection. The composition can be applied as a bath comprising silica fiber powder or dust (e.g., a topical carrier can comprise, consist essentially of, or consist of water and / or another bathing fluid).

[0024] These and other objects and the advantages and features of the invention disclosed herein will become more apparent by reference to the following description, drawings and claims. In addition, it should be understood that the features of the various embodiments described herein are not mutually exclusive and may exist in various combinations and arrangements. As used herein, the terms "approximately", "about" and "substantially" mean ± 10%. Unless otherwise defined herein, the term "substantially consisting of..." means excluding other materials that contribute to the function. However, such other materials may exist in trace amounts, either jointly or individually. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In the accompanying drawings, similar reference numerals generally refer to the same components in different views. In addition, the drawings are not necessarily drawn to scale, but the emphasis is generally placed on illustrating the principles of the invention. In the following description, various embodiments of the invention will be described with reference to the following drawings, in which:

[0026] Figures 1A-1D is a scanning electron microscopy (SEM) image of fibers spun according to the present disclosure. Figures 1A-1D The images in are at scales of 50, 100, 200 and 500 microns, respectively. As shown, the fiber is flexible, smooth, dense and continuous (not broken).

[0027] Figure 2 An SEM image of a fiber spun at a non-optimal time is shown (a scale of 20 microns is shown). The fiber is rigid and breaks are clearly visible.

[0028] Figure 3 A fiber mat spun at a thickness of about 1 / 4 inch according to an embodiment of the present invention is shown. The mat has a soft, flexible texture.

[0029] Figure 4A and 4B The silica fiber mats electrospun at the sol-gel transition according to certain embodiments of the present invention are compared. Figure 4A ) and a fiber mat spun early before the sol-gel is optimally matured ( Figure 4B ).

[0030] Figure 5A and 5B Shown is an SEM image of fiber dust according to an embodiment of the present invention, showing a scale of 100 μm.

[0031] Fig. 6A and 6B Herpes zoster ( Fig. 6A ) and a rash after frequent application for about 1.5 days according to an embodiment of the present invention ( Figure 6B ).

[0032] Fig. 7A Shown is a burn prior to treatment with a silica fiber topical composition according to an embodiment of the present invention.

[0033] Figure 7B shows that after about 4 days of frequent application of a silica fiber topical composition according to an embodiment of the present invention Fig. 7A burns. DETAILED DESCRIPTION

[0034] Embodiments of the present invention provide topical compositions comprising silica fiber powder or dust and a topical carrier. In other aspects, the present invention provides methods for treating aging or damaged skin of a subject. In various embodiments, the method involves applying the composition to improve skin healing, to prevent or reduce scarring, to reduce signs of aging, or to reduce pain or irritation associated with damaged skin. In some embodiments, the composition improves the appearance and appearance of the skin.

[0035] In various embodiments, the topical composition, when applied to the skin, allows the silica fiber dust to be deposited in macroscopic or microscopic cracks in the skin. The fiber dust or flakes act as a collagen mimetic that is substantially non-biodegradable and can promote cell infiltration and / or collagen deposition and, in some embodiments, reduce local pain and the production of inflammatory mediators.

[0036] In various embodiments, the fiber dust is admixed with a topical carrier, which may be in the form of a lotion, ointment, balm, paste, cream, foam, soap, shampoo, or gel, and may contain other active agents.

[0037] The fiber composition is prepared by sol-gel electrospinning a silica fiber composition, then processing the fibers into a fine powder or dust, and admixing the powder or dust with a topical carrier.

[0038] In some embodiments, the silica fiber composition is electrospun from a gel-like material into a lightweight fiber mat. For example, the composition can be prepared by electrospinning a sol-gel, which can be prepared with a silane oxide reagent (such as tetraethyl orthosilicate (TEOS)), an alcohol solvent, and an acid catalyst.

[0039] Known processes for electrospinning silica fibers cannot produce fiber compositions with sufficient flexibility and a texture suitable or ideal for topical compositions. On the contrary, these structures are relatively brittle, rigid and compact; and the fiber mats are thin and easily broken. In general, these materials lack the physical properties to mimic collagen deposition. In various embodiments, in order to obtain excellent materials for tissue repair, it is important to electrospin the sol-gel once it has been properly matured to obtain a composition with the desired physical properties. By slowly maturing the sol-gel under controlled environmental conditions and / or monitoring the sol-gel during the maturation process, a relatively short window for successful electrospinning of the sol-gel can be determined and its duration can be increased. According to an embodiment of the present invention, the composition is non-rigid and has a soft texture similar to cotton.

[0040] According to an embodiment of the present invention, the silica fiber composition, when applied to injured tissue, acts as a non-biodegradable scaffold that supports tissue healing, regeneration and / or integrity. The composition acts as a collagen biomimetic at the site of damaged tissue, thereby providing an environment that is conducive to dermal cell regeneration and growth and / or natural deposition of collagen. Without wishing to be bound by theory, the compositions and methods described herein limit pain and inflammation at the site of damaged tissue. Further, uncontrolled tissue degradation processes can destroy newly deposited collagen. The composition of the present invention provides a non-biodegradable cell scaffold that is not destroyed by proteases released at the site of tissue damage, but provides an optimal environment for the colonization and growth of dermal cells. The fiber will become an integral part of the regenerated tissue.

[0041] The fiber may have a variable or more uniform diameter, such as in the range of about 50 nm to 5 μm. In some embodiments, the fiber is primarily in the range of about 100 nm to about 2 μm, or primarily in the range of about 200 nm to about 1000 nm. One or more dimensions of the fiber are better mimics of native collagen than, for example, fragile scaffolds, including those intended to have a more uniform structure.

[0042] In some embodiments, a sol-gel for preparing a silica fiber mat is prepared by a method comprising the following steps: preparing a first mixture containing an alcohol solvent, a silane oxide reagent (such as tetraethyl orthosilicate (TEOS)); preparing a second mixture containing an alcohol solvent, water and an acid catalyst; titrating the second mixture completely into the first mixture; and processing (ripening) the combined mixture to form a gel for electrospinning. In some embodiments, the silane oxide reagent is TEOS. Alternative silane oxide reagents include those having the formula Si(OR)4, wherein R is 1 to 6, and preferably 1, 2 or 3.

[0043] In some embodiments, the sol comprises, consists essentially of, or consists of about 70% to about 90% by weight of a silane oxide (e.g., TEOS), about 5% to about 25% by weight of an alcohol solvent (e.g., anhydrous ethanol), an acid catalyst (e.g., less than about 0.1% by weight when HCl is used), and water. Any sol or sol-gel described herein may include a balance of water (i.e., water may constitute any amount of the sol or sol-gel not otherwise specified). Any sol or sol-gel described herein may optionally contain one or more agents that may or do alter one or more properties of the sol, sol-gel, and / or silica fiber. Such agents may include, but are not limited to, for example, polymers and polymer solutions, inert agents, alcohols, organic and / or aqueous solvents, organic salts, inorganic salts, metals, metal oxides, metal nitrides, metal oxynitrides, carbon (e.g., graphene, graphite, fullerenes, etc.), and the like.

[0044] In some embodiments, the colloidal sol contains 70% to 90% by weight of tetraethyl orthosilicate (TEOS), 8% to 25% by weight of ethanol, 1% to 10% by weight of water, and an acid catalyst. In some embodiments, the colloidal sol contains 75% to 85% by weight of TEOS, 12% to 20% by weight of ethanol and about 2% to 5% by weight of water. Exemplary colloidal sol contains about 80% by weight of TEOS, about 17% by weight of ethanol and about 3% by weight of water. In some embodiments, the acid catalyst is HCl. For example, the colloidal sol can contain less than about 0.1% by weight of HCl. For example, the colloidal sol can contain 0.02% to 0.08% by weight of HCl. In various embodiments, the colloidal sol does not include organic polymers or other large amounts of reagents so that the fiber composition will be substantially pure SiO . In various embodiments, the sol does not include inorganic salts (e.g., sodium chloride, lithium chloride, potassium chloride, magnesium chloride, calcium chloride, and / or barium chloride), nor in various embodiments are inorganic salts mixed with other components of the sol or mixed into the sol itself. In various embodiments, the fiber composition does not include metals or metal oxides (e.g., TiO2 or ZrO2). In various embodiments, the fiber composition consists essentially of SiO2, i.e., contains only SiO2 and unintentionally added impurities, and in some embodiments also contains substances and / or complexes resulting from incomplete conversion of the sol to SiO2 (e.g., water and / or chemical groups such as ethoxy, silanol, hydroxyl, etc.).

[0045] In some embodiments, the alcohol solvent is anhydrous denatured ethanol, or in some embodiments, the alcohol solvent is methanol, propanol, butanol or any other suitable alcohol solvent. The first mixture can be stirred, for example, using a magnetic stirrer, a vibrating platform or a vibrating platform or other stirring devices. The second mixture contains an alcohol solvent, water and an acid catalyst. The alcohol solvent can be anhydrous denatured alcohol, or can be methanol, propanol, butanol or any other suitable alcohol solvent provided. Water can be distilled water or deionized water. Enough acid catalysts are added to the mixture to help the reaction. This acid catalyst can be hydrochloric acid, or can be sulfuric acid or other suitable acid catalysts. The second mixture can be stirred, for example, using a magnetic stirrer, a vibrating platform or a vibrating platform or other stirring devices. In some embodiments, the first mixture (or sol) and the second mixture (or sol) are prepared without using direct heating (that is, heat applied by external means such as hot plates or other heat sources).

[0046] According to various embodiments, the first and second mixtures are combined by adding or titrating the second mixture into the first mixture, preferably with agitation. The combined mixture is then further processed by allowing the sol to mature in a controlled environment until a substantial portion of the alcohol solvent has evaporated to produce a sol-gel suitable for electrospinning. For example, the controlled environment may include an enclosure having at least one vent and optionally a fan for drawing gas from the mixture, and the controlled environment may involve controlled conditions in terms of humidity, temperature, and optionally atmospheric pressure. For example, humidity can be controlled (e.g., via the use of a conventional humidifier and / or dehumidifier) ​​in the range of about 30% to about 90% (such as about 40% to about 80%, or in some embodiments, about 50% to about 80%, or about 50% to about 70% (e.g., about 55%, or about 60%, or about 65%). Some humidity can help slow evaporation of the solvent, thereby extending the window for successful electrospinning. In some embodiments, the temperature is in the range of about 50°F to about 90°F (such as about 60°F to about 80°F or about 65°F to about 75°F). In various embodiments, the sol is not exposed to heating in excess of 150°F or in excess of 100°F to avoid accelerating the transition. In some embodiments, the atmospheric pressure is optionally controlled (e.g., using a low pressure vacuum source, such as a pump or fan). By controlling the environmental conditions during aging, the gel can be subjected to extended aging. The time period for electrospinning; if the aging process is accelerated too much (such as by direct heating), this time period may be a small window of only a few minutes. When the sol is aged at a constant humidity of about 55% and a temperature of about 72°F, the sol will mature (gel) within a few days, and the window for successful electrospinning can be extended to at least a few hours, and in some embodiments, a few days. In various embodiments, the aging process takes at least 2 days, or at least 3 days in some embodiments. However, in various embodiments, the aging process takes no more than 10 days or no more than 7 days. In some embodiments, the aging process takes 2 to 10 days, or 2 to 7 days, or 2 to 5 days, or 2 to 4 days (such as, about 2 days, about 3 days, or about 4 days). In various embodiments, the sol-gel has good spinnability before it is transformed into a more solidified, non-flowable mass.

[0047] The enclosed space for sol-gel aging may include a vent on at least one surface for gas to be discharged from the enclosed body, and optionally, the vent may include a fan for discharging the gas produced during the aging process. The enclosed space may optionally include a heating source (e.g., one or more heating elements, such as a resistance heating element) for providing a nominal amount of heat to maintain a preferred temperature in the enclosed space. In some embodiments, a humidity source (e.g., an open container of water or other aqueous, water-based liquids) is provided in a closed environment to adjust humidity to a desired range or value. The enclosed body may also include one or more environmental monitors, such as a temperature reading device (e.g., a thermometer, a thermocouple or other temperature sensors) and / or a humidity reading device (e.g., a hygrometer or other humidity sensors).

[0048] In some embodiments, after a aging process of at least 2 days, or at least 36 hours, or at least 3 days, or at least 4 days, or at least 5 days (but in various embodiments, no more than 10 days or no more than 7 days under controlled environmental conditions) under controlled environmental conditions, the sol-gel is electrospun. By slowing down the aging process, the ideal time for spinning the fiber can be identified. The weight of the sol-gel can be used as an indicator of when the sol-gel is at or close to the ideal time for electrospinning. Without being bound by theory, it is believed that the viscosity of the sol-gel is a poor determinant for identifying the best time for electrospinning. For example, in various embodiments, the sol-gel is about 10% to about 60% of the original weight of the sol (based on the loss of alcohol solvent during the transition). In some embodiments, the sol-gel is 15% to 50% of the original weight of the sol, or in the range of about 20% to about 40% of the original weight of the sol.

[0049] In some embodiments, the sol-gel is ripened for at least 2 days, or at least 36 hours, or at least 3 days, or at least 4 days, or at least 5 days, and when the ethylene vapor produced by the composition is between about 10% and about 40% of the steam produced by the initial sol, such as in the range between about 10% and about 25%, or in the range of about 10% to about 20%, the sol-gel is electrospun. Ethylene is a colorless, flammable gas with a light sweetness and musky smell (slowed down by solvent evaporation, this light sweetness and musky smell are obvious). Ethylene is generated by ethanol and acid reaction. Conventional ethylene monitors can be optionally used to monitor the ethylene in the steam. In other embodiments, the gas produced by the sol during the sol ripening process is monitored to determine the suitable or optimal time for electrospinning. Gas chromatography can be used to monitor gas distribution.

[0050] In various embodiments, the sol-gel can be matured for a shorter period of time, as long as the sol-gel can still be spun via electrospinning. After maturing for a shorter period of time, the resulting silica fiber mat or fiber assembly may be more brittle in some cases, but such brittleness may not prevent the fibers from fragmenting and dispersing into various topical compositions.

[0051] Processing of the sol-gel mixture may require stirring or other agitation of the mixture at various intervals or continuously due to the formation of silica crystalline material on the top surface of the mixture. This formation of crystalline material on the top surface slows down the processing time, and it is believed that the crystalline material seals the mixture from exposure to the gaseous vacuum provided in the enclosed space. In some embodiments, any solid crystalline material is removed from the mixture.

[0052] After the sol-gel process is completed, the sol-gel is then electrospun using any known technique. If desired, the sol or sol-gel can be stored (e.g., frozen or refrigerated) (and such time will generally not be suitable for aging). Choi, Sung-Seen et al., Silica nanofibers from electrospinning / sol-gel process An exemplary process for electrospinning a sol-gel is described in Journal of Materials Science Letters 22, 2003, 891-893, which is hereby incorporated by reference in its entirety. An exemplary process for electrospinning is further disclosed in U.S. Pat. No. 8,088,965, which is hereby incorporated by reference in its entirety.

[0053] In an exemplary electrospinning technique, sol-gel is placed in one or more injection pumps that are fluidically coupled to one or more spinnerets. The spinneret is connected to a high voltage (e.g., 5kV to 50kV) source and is outside a grounded collector drum and facing a grounded collector drum. The drum is generally rotated along a rotation axis that is roughly perpendicular to the spinning direction extending from the spinneret to the drum during spinning. When the sol-gel is supplied to the spinneret from the injection pump (or other storage tank), the high voltage between the spinneret and the drum form forms a charged liquid jet, which is deposited on the drum as a fine entangled fiber. As the drum rotates and electrospinning continues, a fiber mat of silica fibers is formed around the circumference of the drum. In various embodiments, the spinneret and one or more injection pumps may be arranged on a movable platform, and the platform may be moved parallel to the length of the drum. In this way, the length of the resulting fiber mat along the drum can be increased without increasing the number of spinnerets. The diameter of the drum may also be increased to increase the area size of the electrospun mat. The thickness of the mat can depend largely on the amount of sol-gel used for spinning, and therefore on the amount of electrospinning time. For example, the thickness of the mat can be greater than about 1 / 8 inch, or greater than about 1 / 4 inch, or greater than about 1 / 3 inch, or greater than about 1 / 2 inch.

[0054] After the electrospinning process is completed, the resulting pad is removed from the drum. For example, the pad can be cut into one or more pieces and peeled off from the drum with one or more pieces. The pad can then be separated into small fiber fragments, which can be incorporated into a topical composition. In various embodiments, the resulting fiber fragments are a collection of silica fibers entangled together, rather than a single solid particle. In some embodiments, the electrospun pad can be broken, cut, ground, milled, or otherwise divided into small fragments that maintain a fiber structure. In some embodiments, the pad (or one or more parts thereof) is rubbed through one or more screens or screens, and the mesh size of the screen determines at least in part the size of the resulting fiber fragments or powder or dust produced by the electrospun pad. For example, the pad or pad portion can be rubbed through two or more continuous screens with a continuously decreasing mesh size (e.g., a screen with a mesh number of 100, 200, 300 or even 400) to produce a powder or dust or collection of fiber fragments with a desired size.

[0055] Fiber dust or fiber fragments are blended with a topical carrier, which can be in the form of an emulsion, ointment, balm, paste, cream, foam, soap, shampoo, conditioner or gel. The topical composition can be a skin care composition or a cosmetic composition. In some embodiments, the fiber dust or fragments are distributed in a carrier system such as water or any aqueous solution containing organic or inorganic materials. The composition can contain one or more ingredients to change or enhance its texture, appearance, odor performance or stability. The illustrative additives of the composition include: an oily component, a fat component, an ointment base, a hydrophilic solvent, a lipophilic solvent, an emollient, water, a buffer, a pH adjusting agent, a preservative, a wetting agent, a chelating agent, an antioxidant, a stabilizer, an emulsifier, a detergent, a suspending agent, a gel forming agent, perfumes and flavors, a skin protectant and a preservative.

[0056] In various embodiments, fiber dust or fiber fragments are incorporated into the composition at about 5 mg / ml to about 500 mg / ml, or about 5 mg / ml to about 400 mg / ml, or about 5 mg / ml to about 250 mg / ml. In some embodiments, the dust or fiber fragments are incorporated into the composition at about 10 mg / ml to about 200 mg / ml, or about 10 mg / ml to about 150 mg / ml, or about 25 mg / ml to about 100 mg / ml.

[0057] The topical composition can include an oily or fatty component, which is a component of the hydrophobic phase and can include one or more of the following: almond oil, castor oil, cocoa butter, coconut oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, poppy seed oil, rapeseed oil, sesame oil, soybean oil, sunflower seed oil, tea seed oil, jojoba oil, mineral oil, silicone oil, fatty oil, liquid paraffin, beeswax, lanolin, white soft paraffin, yellow soft paraffin, petrolatum, triglycerides, cetyl alcohol, stearyl alcohol, isopropyl myristate, oleic acid, isopropyl palmitate, stearic acid, sorbitan esters of fatty acids, sorbitan esters of fatty acids and ethylene oxide (including Tween).

[0058] The topical composition can include an aqueous phase, which constitutes the hydrophilic phase and can include water, one or more other hydrophilic solvents and / or one or more surfactants and / or emulsifiers. In various embodiments, the aqueous phase can include a solvent such as water, polyethylene glycol, propylene glycol, glycerol, sorbitol, and an alcohol such as ethanol and isopropanol.

[0059] The composition may include one or more emulsifiers (emulsifying agents), which may be part of the aqueous phase and / or the oil phase. The term "emulsifier" means an amphiphilic molecule having polar and non-polar regions, which are covalently linked and capable of reducing the surface tension of water and the interfacial tension between water and an immiscible liquid. Emulsifiers include soaps, detergents, surfactants, etc. Emulsifiers may be cationic, anionic, nonionic or amphoteric. Exemplary emulsifiers include nonionic emulsifiers, such as polyol esters (such as propylene glycol monoesters of ethylene glycol, diethylene glycol, glycol stearates and fatty acids) and glycerides (such as stearic acid glyceryl ester, monooleic acid glyceryl ester, monolauric acid glyceryl ester, ricinoleic acid glyceryl ester, monocaprylic acid glyceryl ester). Exemplary emulsifiers also include sorbitan derivatives, which are esters of cyclic anhydrides of sorbitol and fatty acids. These include sorbitan monolaurate, sorbitan monooleate, sorbitan monostearate, sorbitan monopalmitate, sorbitan sesquioleate, sorbitan trioleate, sorbitan tristearate, polyoxyethylene sorbitan esters (such as polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tristearate, polyoxyethylene sorbitan monooleate). Exemplary emulsifiers also include such polyoxyethylene esters, which are mixtures of mono- or di-fatty acid esters (C12 to C18) of polyoxyethylene glycol. These include stearates of PEG (PEG-40, PEG-50 and PEG-55), and laurates, oleates and myristates of PEG.

[0060] The composition may comprise a polymeric thickener, including gums such as acacia, alginates, carrageenan, chitosan, collagen, tragacanth and xanthan gum; cellulose, acrylic acid, colloidal solids such as silica, clays and microcrystalline cellulose, hydrogels such as polyvinyl alcohol and polyvinyl pyrrolidone, and thermoreversible polymers such as poloxamers.

[0061] The composition may also include one or more pharmaceutical agents suitable for topical application or antimicrobial agents. Exemplary pharmaceutical agents include anti-fibrotic agents and anti-scarring agents.

[0062] In some embodiments, the composition comprises an antibiotic or a preservative. Antibiotics suitable for use in the present invention include, but are not limited to, cephalosporin antibiotics, tetracycline antibiotics, beta-lactams, carbapenem antibiotics, polymyxin B (neosporin), neomycin, and bacitracin. Preservatives include, but are not limited to, phenol, meta-cresol, methyl parahydroxybenzoate, and sodium benzoate.

[0063] In some embodiments, the composition further comprises one or more anti-inflammatory agents, such as steroidal anti-inflammatory agents or nonsteroidal anti-inflammatory agents (NSAIDs). Steroids, particularly adrenocortical steroids and synthetic analogs thereof are well known in the art. Examples of corticosteroids include, but are not limited to, hydroxytriamcinolone, α-methyldexamethasone, β-methylbetamethasone, beclomethasone dipropionate, clobetasol valerate, dexasonide, deoxymethasone, dexamethasone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fluocortol ... acetonide), flumethasone pivalate, fluocinolone acetate, fluocinolone, fluocinolone butyl, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolide, halcinonide, triamcinolone acetonide, cortisone, cortodoxone, fluocinolone acetonide, fludrocortisone, difluroxolone diacetate, fluocinolone acetonide, medrysone, amcinafil, amcifetil, betamethasone, cloprednisone, clocortolone, decilone, diclofenac, difluprednate, fluclofenac, flunisolide, fluorometholone, fluperone, fluprednisolone, hydrocortisone, paramethasone, prednisolone, methylprednisolone, prednisone, and budesonide. NSAIDs that can be used in the composition include salicylic acid, acetylsalicylic acid, methyl salicylate, glycol salicylate, salicylamide, benzyl-2,5-diacetoxybenzoic acid, ibuprofen, fulindac, naproxen, ketoprofen, etofenamate, phenylbutazone, and indomethacin. In some embodiments, the composition comprises at least one active agent for relieving pain, including but not limited to cortisone, hydrocortisone, acetaminophen, or cannabinoids.

[0064] In various embodiments, the present invention provides a method for treating skin tissue in a subject. The method comprises applying a topical composition as described herein to the skin tissue. The composition can be applied routinely or regularly. In some embodiments, the composition is applied at least about every day, and in some embodiments, is applied 1 to about 10 times every day. In various embodiments, the method improves the healing of skin tissue and / or prevents or reduces tissue scarring, skin laxity, signs of aging, pain, and / or irritation.

[0065] The application of the composition can provide improved or accelerated healing of damaged skin. For example, when the topical composition is applied to skin with cracks, small abrasions, blemishes, etc., the scaffold will remain in the small "wound" to allow cells to grow in. This speeds up the healing process and helps to reduce scar formation. In some embodiments, the composition of the emulsion or other forms is applied to the cracked skin (e.g., on the face, mouth or lips, neck, hands, arms, shoulders, legs, scalp, fingers, etc.) to improve the tolerance of the skin to the environment (such as sun exposure, wind and cold), thereby reducing the impact of age and environment on the appearance, touch and / or function of the skin. In some embodiments, the composition is a lip balm, which may include silica dust suspended in a wax base (such as carnauba wax, paraffin and / or beeswax). Alternatively, the lip balm can be an ointment, such as an ointment containing vaseline or a similar matrix (including a matrix described herein). In other other embodiments, the composition is applied as soap or shampoo during bathing. In some embodiments, the silica composition is a bath salt for bathing.

[0066] In some embodiments, the composition is applied to insect or spider bites or stings (including bee stings, wasp stings, mosquito bites, spider bites, flea bites, fly or ant bites, bed bug bites, etc.). In some embodiments, the composition is applied to skin that has been in contact with poison ivy or poison oak or shows a reaction to poison ivy or poison oak. In other embodiments, the composition is applied to skin allergic reactions or urticaria. The composition in these embodiments may include additional agents to relieve itching or swelling (such as corticosteroids or antihistamines), pain (such as acetaminophen or NSAIDs), or allergic reactions (such as antihistamines). Exemplary antihistamines include brompheniramine, carbenoxamine maleate, chlorpheniramine, clemastine, diphenhydramine, hydroxyzine triprolidine, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine and olopatadine.

[0067] In some embodiments, the composition is applied to skin showing signs of microbial infection, including HPV (e.g., warts), herpes simplex virus (e.g., cold sores), varicella-zoster virus (e.g., chickenpox or shingles), fungal infection (e.g., candidiasis or tinea versicolor), or staphylococcal infection or overcolonization. In some embodiments, the composition comprises one or more antibiotics (e.g., antibacterial or antifungal agents), antiviral agents, or antiseptics.

[0068] In some embodiments, the subject is a mammal. The subject includes a veterinary patient, such as a dog, cat, or horse, etc. In some embodiments, the patient is a human patient. In some embodiments, the patient is a pediatric patient.

[0069] In some embodiments, the composition is applied to skin lesions, superficial wounds or infections (such as acne), burns, cuts, abrasions, rashes (such as diaper rash), blisters (including ruptured blisters) or urticaria. In some embodiments, the composition is applied to cracked or abraded skin. In some embodiments, the composition is applied to aging skin or dry skin, including eczema, atopic dermatitis or pruritus. In some embodiments, the topical composition normalizes the tissue microenvironment, and can reduce pain and inflammation at the site, and / or provide micro-scaffolds for skin cell proliferation and growth, and induce collagen deposition in some embodiments. In some embodiments, the subject suffers from first, second or third degree burns, or a combination thereof. In some embodiments, the composition is applied to sunburns, and pain or discomfort is reduced. In some embodiments, the composition is applied to postoperative wounds, including skin grafts, skin containing sutures, or cosmetic surgery wounds.

[0070] For the treatment of severe wounds and burns, it may first be necessary to apply a portion of the fiber pad directly to the wound for a few days (see US 10,111,783, which is hereby incorporated by reference in its entirety). Once new skin is substantially formed over the wound or burn area, the subject transitions to applying the lotion described herein. The lotion is generally applied once or more per day and can be used continuously until the skin barrier is normalized.

[0071] In some embodiments, the composition is applied to age spots (eg, solar lentigo). Regularly (eg, at least daily) applying the composition for several days can fade or reduce visible age spots.

[0072] In some embodiments, because the fibrous material substantially reduces pain from the site of tissue damage, a patient may be able to forgo therapy with pain medications such as opioids.

[0073] In some embodiments, the subject has a genetic disease that affects skin barrier function, such as, but not limited to, epidermolysis bullosa or ichthyosis.

[0074] Epidermolysis bullosa (EB) is a group of primarily inherited connective tissue disorders that cause blistering of the skin and mucous membranes. This is due to defects in the anchoring between the epidermis and dermis, resulting in friction and skin fragility. EB often involves the formation of blisters after minor trauma.

[0075] In some embodiments, the subject suffers from simplex epidermolysis bullosa, which causes blisters at sites of friction and usually affects the hands and feet. In some embodiments, the subject suffers from conjunctive epidermolysis bullosa, which affects laminin and collagen. Conjunctive epidermolysis bullosa also causes blisters at sites of friction, particularly on the hands and feet. Dystrophic epidermolysis bullosa is a genetic variation that affects the skin and other organs and involves very fragile skin. Dystrophic epidermolysis bullosa is caused by a genetic defect (or mutation) in the gene encoding the protein type VII collagen (collagen VII).

[0076] Human skin consists of two layers: the outermost layer, called the epidermis, and the lower layer, called the dermis. In individuals with healthy skin, there are protein anchors between these two layers that prevent them from moving (shearing) independently of each other. In people born with EB, the two skin layers lack the protein anchors that hold them together, resulting in very fragile skin. Even minor mechanical friction (such as rubbing or pressure) or trauma will separate the skin layers and form blisters and painful sores. EB patients have compared the sores to third-degree burns.

[0077] In some embodiments, the subject suffers from ichthyosis. Ichthyosis is a family of hereditary skin disorders characterized by dry, thickened, scaly skin. More than 20 types of ichthyosis differ in the severity of symptoms, appearance, and potential genetic causes. The severity of symptoms may vary from the mildest, most common types (such as ichthyosis vulgaris, which can be mistaken for normal dry skin) to life-threatening conditions (such as harlequin ichthyosis). In various embodiments, the topical composition is applied to a subject suffering from any type of ichthyosis (including harlequin ichthyosis).

[0078] In some embodiments, the composition is applied to diseased skin, which may be a manifestation of a proliferative disorder (such as cancer, precancerous lesions or melanoma lesions, or other cancerous lesions or psoriasis), or in some embodiments, an autoimmune or inflammatory disorder. For example, in some embodiments, the composition is applied for the treatment of rosacea or acne. Autoimmune manifestations include skin manifestations of lupus and dermatitis herpetiformis or dermatomyositis. In some embodiments, the composition is applied to skin affected by herpes zoster, thereby providing, for example, relief of associated pain and reduction of associated rashes. In some embodiments including but not limited to subjects experiencing herpes zoster, psoriasis or eczema, the composition may be topically applied to the affected area of ​​the skin, or alternatively, the composition may be applied during bathing (using soap, shampoo or bath salt compositions containing silica dust).

[0079] In some embodiments, other conditions that benefit from the composition include neuropathy, joint pain, and gout. In some embodiments, the composition is applied to the skin in the painful area (eg, to the substantially intact skin surrounding the painful joint).

[0080] In some embodiments, the composition is applied to the affected area at least about every day, for at least about 1 week or at least about 2 weeks. In some embodiments, the composition is applied once to ten times every day, or in some embodiments, applied once to about four times every day, or applied once to three times every day. In some embodiments, the scheme lasts at least one week, or at least two weeks, or at least one month, or at least two months, or at least four months, or at least six months or longer. In some embodiments, the scheme lasts six months or longer. For a subject suffering from a genetic disease of the skin, the scheme can be continuous.

[0081] Embodiments of the present invention will now be described with reference to the following examples.

[0082] Example

[0083] Example 1: Preparation of silica fiber mat

[0084] The silica fibers are prepared using an electrospinning process in which a sol-gel is spun onto a collection drum to form a nonwoven mat of fibers. The sol-gel is prepared in two parts. First, TEOS is mixed with ethanol, and then a second mixture containing HCl, water, and ethanol is titrated into the mixture. The sol-gel is then allowed to mature under controlled conditions for several days before spinning.

[0085] In one embodiment, a first sol is prepared by weighing out 384 grams of TEOS 98% and 41.8 grams of anhydrous denatured ethanol and pouring them together. The first sol is allowed to stand in a beaker and a magnetic stirrer is used to produce a homogenous solution. A second sol is prepared by weighing 41.8 grams of anhydrous denatured ethanol, 16.4 grams of distilled water, and 0.34 grams of hydrochloric acid, then pouring them together and mixing them for 8 seconds with a magnetic stirrer until a homogenous second sol is formed.

[0086] The second sol is then poured into a titration apparatus placed above the beaker containing the first sol. The titration apparatus then drips about 5 drops per second until a third sol is formed by mixing the first sol with the second sol. During the dripping process, the first sol is continuously mixed with a magnetic stirrer while the second sol is dripped into the first sol.

[0087] The combined third sol is then placed in a closed box. A fan is used to provide a low pressure vacuum at a medium speed to remove smoke. The air temperature in the box is 72°F and the humidity is 60%. The third sol is allowed to stand and process for about three days. The mixture is stirred every day to reduce the formation of a crystalline structure. As the alcohol solvent evaporates, the third sol begins to transform into a sol-gel. The sol-gel can be monitored to determine the approximate amount of C2H4 (ethylene) in the steam, which can be within the range of about 10-20% relative to the amount of the initial sol before aging. After appropriate gelation, the sol-gel is loaded into an electrospinning machine or frozen for electrospinning. In this embodiment, appropriate gelation occurs when the total mass of the sol-gel is between about 70 grams and about 140 grams. This embodiment can be appropriately scaled, and the range can vary, while still producing the desired structure. In order to further determine the ideal time for electrospinning, a portion of the gel can be dripped into the electric field of the electrospinning device to evaluate the electrospinning properties of the sol-gel.

[0088] Figures 1A-1D are scanning electron microscopy (SEM) images of fibers spun according to embodiments of the present disclosure (scales of 50, 100, 200, and 500 microns are shown). As shown, the fibers are flexible, smooth, dense, and continuous (without significant breaks). Figure 2 is a SEM image (showing a 20 micron scale) of a fiber electrospun at a non-optimal time (before the sol-gel is fully ripened), where the fiber is clearly rigid and numerous breaks are clearly visible. Figure 3 A spun fiber mat according to an embodiment of the present invention is shown. The flexibility and continuity of the fibers enable the mat to be spun to a thickness of 1 / 4 inch or greater. The mat has a soft, flexible texture.

[0089] Figure 4A and 4B is a comparison of the silica fiber mat ( Figure 4A ) and sol-gel fiber mats that are spun prematurely or ripen too quickly before being optimally ripened ( Figure 4B )’s picture. Figure 4A The material in has a soft texture, is very flexible, and can be spun to a thickness that is easily processed into dust-like particles. Figure 4B The material in is brittle, inflexible and thin.

[0090] A silica fiber mat is made and broken into fragments by rubbing through a series of screens with decreasing mesh sizes. The final screen is a 200 mesh screen, producing fiber dust and / or fiber fragments having a size of about 20 μm to about 200 μm. Figure 5A and 5BAn SEM image of the resulting fiber dust is shown, showing a scale of 100 μm. The soft texture of the material is still evident in the dust form.

[0091] For incorporation into topical compositions, the silica fiber mat prepared as described above was rubbed through a 100 mesh screen. The resulting silica fiber dust was incorporated into different topical compositions including: petrolatum, bacitracin ointment, face cream, hand cream, and acne cream.

[0092] Example 2: Treatment of herpes zoster

[0093] A paste was prepared with bacitracin ointment and silica fiber dust. The paste was applied to the skin of a middle-aged woman experiencing herpes zoster. The ointment relieved the pain associated with herpes zoster. A petrolatum-silica fiber composition was also applied to the affected area with similar results.

[0094] Exemplary treatments for herpes zoster are Fig. 6A and 6B Shown in. Fig. 6A shows the initial shingles rash, while Figure 6B The same rash is shown about 1.5 days after application of the topical composition. The pain is also significantly reduced. Typically, shingles takes several weeks to resolve.

[0095] Example 3: Treatment of age spots

[0096] A silica fiber composition prepared with a general purpose face cream was prepared as described. The composition was applied to age spots on the face of an adult male over the course of 10 days. Within ten days, the spots had substantially disappeared.

[0097] Example 4: Treatment of scar tissue

[0098] The silica fiber composition was prepared with a general purpose hand cream. Adult females with scarring and dermatitis marks on their hands used the composition regularly. Over time, the scarring and dermatitis marks subsided.

[0099] Example 5: Treatment of acne

[0100] A silica fiber composition was prepared with acne cream and applied to the face of a woman with acne blemishes and acne scarring. With regular application, the scars and blemishes subsided.

[0101] Example 6: Burn Treatment

[0102] The silica fiber composition was applied to the torso of a middle-aged male with first / second degree burns. With conventional application, the burns were substantially healed in about 4 days (approximately Fig. 7A and Figure 7B for comparison).

[0103] In another example, a middle-aged male sustained 2nd and 3rd degree burns from an explosion. The burns covered the right hand and most of the right arm, extending from the fingers to above the elbow. Treatment with silica fibers began about a week after the accident. Prior to treatment, the subject was still experiencing a considerable amount of pain. The pain was reported to be significantly relieved within a few minutes of applying the fibers to the wound. A feeling of tightness was reported.

[0104] Once the fibers were removed by showering, the pain returned, albeit at a reduced level. With further application of the fibers, the pain was significantly relieved again. By the next day, the silica matrix would not simply wash off the wound by showering. For the next week, the burn was coated with the fiber matrix 2 to 3 times daily. By the 3rd day, the skin began to grow back. After a little over a week, most of the skin had grown back over the wound area.

[0105] Once new skin has formed over the burned area, treatment transitions to a lotion containing a silica base. The lotion is applied to the burned area two to four times a day, as necessary. After a few weeks of using the lotion, there is no visible scarring from the burn. There is a slight discoloration of the skin's pigmentation, which fades over time.

[0106] Example 7: Treatment of ichthyosis

[0107] The emulsion composition was applied to the skin of a female subject (approximately 18 months old) with harlequin ichthyosis. It was observed that the rate of excess skin production was dramatically reduced. It was further observed that the subject's body was more hydrated, most likely due to the slower rate of skin production and greatly reduced extremely high caloric requirements.

[0108] The terms and expressions employed herein are used as descriptive terms and expressions rather than limiting terms and expressions, and when such terms and expressions are used, there is no intention to exclude any equivalents of the features shown and described or parts thereof. In addition, certain embodiments of the present invention have been described, and it will be apparent to those of ordinary skill in the art that other embodiments incorporating the concepts disclosed herein may be used without departing from the spirit and scope of the present invention. Accordingly, the described embodiments should be considered to be illustrative in all respects only and not restrictive.

Claims

1. A topical composition comprising silica fiber powder or dust, and a topical carrier comprising a hydrophobic phase and an aqueous phase, wherein the composition is prepared by electrospinning a sol-gel into a silica fiber composition, processing the silica fiber composition into a powder or dust, and admixing the powder or dust with the topical carrier, wherein the sol-gel is produced from an initial sol comprising 70 wt % to 90 wt % of tetraethyl orthosilicate (TEOS), 8 wt % to 25 wt % of ethanol, an acid catalyst and 1 wt % to 10 wt % of water, The hydrophobic phase comprises almond oil, castor oil, cocoa butter, coconut oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, poppy seed oil, rapeseed oil, sesame oil, soybean oil, sunflower seed oil, tea seed oil, jojoba oil, mineral oil, silicone oil, fatty oil, liquid paraffin, beeswax, lanolin, white soft paraffin, yellow soft paraffin, vaseline, triglycerides, cetyl alcohol, stearyl alcohol, isopropyl myristate, oleic acid, isopropyl palmitate, stearic acid, sorbitan esters of fatty acids, and sorbitan esters of fatty acids and ethylene oxide.

2. The topical composition of claim 1, wherein the topical carrier is an emulsion.

3. The topical composition of claim 2, wherein the composition further comprises one or more pharmaceutical agents.

4. The topical composition of claim 2, wherein the composition further comprises one or more antimicrobial agents.

5. The topical composition of claim 4, wherein the composition comprises an antibiotic or an antiseptic.

6. The topical composition of claim 3, wherein the topical composition comprises an anti-inflammatory agent, an immunosuppressant, or a pain-relieving agent.

7. The topical composition of claim 3, further comprising an anti-fibrotic or anti-scarring agent.

8. The topical composition of claim 1, wherein the initial sol is aged for at least 2 days under the conditions where the humidity is controlled within the range of 40% to 80% and the temperature is controlled within the range of 50°F to 90°F.

9. The topical composition of claim 8, wherein the initial sol is allowed to mature for 2 to 7 days.

10. The topical composition of any one of claims 1 to 9, wherein the sol-gel is electrospun when the weight is 10% to 60% of the starting weight before ripening.

11. The topical composition of any one of claims 1 to 9, wherein the sol-gel is electrospun when the emission of ethylene vapor is 10% to 40% relative to the sol before ripening.

12. The topical composition of any one of claims 1 to 9, wherein the fibers have a variable diameter of 50 nm to 5 μm.

13. The topical composition of claim 12, wherein the fibers have a variable diameter predominantly in the range of 200 nm to 2000 nm.

14. The topical composition of any one of claims 1 to 9, wherein the silica fiber powder or dust is composed of SiO 2 composition.

15. The topical composition of claim 1, wherein the aqueous phase comprises a solvent comprising one or more of water, polyethylene glycol, propylene glycol, glycerin, sorbitol, ethanol, and isopropanol.

16. Use of the topical composition of any one of claims 1 to 15 in the preparation of a medicament for treating skin tissue of a subject.

17. The use according to claim 16, wherein the use improves the healing of the skin tissue and / or prevents or reduces tissue scarring, pain and / or irritation.

18. The use of claim 16, wherein the subject is a mammal.

19. The use of claim 18, wherein the subject is a veterinary patient.

20. The use of claim 19, wherein the subject comprises a dog, a cat or a horse.

21. The use of claim 18, wherein the subject is a human patient.

22. The use of any one of claims 16, wherein the composition is applied to a skin lesion, scar, superficial wound or infection, burn, cut, scrape, rash, blister, insect bite, poison ivy or poison oak, or hives.

23. The use of claim 22, wherein the subject suffers from a genetic disease affecting skin integrity.

24. The use according to claim 23, wherein the subject suffers from epidermolysis bullosa or ichthyosis.

25. The use of claim 22, wherein the subject suffers from first, second and / or third degree burns.

26. The use of claim 22, wherein the composition is applied to sunburn.

27. The use of claim 22, wherein the composition is applied to a melanoma lesion.

28. The use of claim 16, wherein the composition is applied to aged skin, age spots, dry skin, cracked skin, or scar tissue.

29. The use of claim 16, wherein the composition is applied to skin affected by eczema or atopic dermatitis.

30. The use of claim 16, wherein the composition is applied to skin affected by psoriasis.

31. The use of claim 16, wherein the composition is applied to skin affected by acne.

32. The use of claim 16, wherein the composition is applied to skin affected by rosacea.

33. The use of claim 16, wherein the composition is applied to a post-operative wound or suture.

34. The use of claim 16, wherein the composition is applied to skin affected by itching.

35. The use of claim 16, wherein the composition is applied to skin affected by herpes zoster or lupus.

36. The use of claim 16, wherein the subject suffers from neuropathy, arthralgia or gout.

37. The use of claim 16, wherein the composition is applied to skin affected by dermatitis herpetiformis or dermatomyositis.

38. The use of claim 16, wherein the composition is applied to skin showing signs of microbial infection.

39. The use of claim 38, wherein the microbial infection is HPV, herpes simplex virus, varicella-zoster virus, fungal infection or staphylococcal infection.